Fabrication of cyclodextrin nanosponges for quercetin delivery: physicochemical characterization, photostability, and antioxidant effects
Source abstract
Abstract
Quercetin is a flavonoid widely distributed in vegetables and fruits and exhibits strong antioxidant activity, but the poor solubility and stability of quercetin limit its function and application. The purpose of this study was to enhance the dissolution rate and stability of a poorly water-soluble drug quercetin by complexation with cyclodextrin-based nanosponges. Nanosponges are recently developed sponge-like structures and have the capacity to interact with small molecules in its matrix. In this study, five types of nanosponges were purposely designed by varying the molar ratio of β-cyclodextrin and diphenyl carbonate. Quercetin was loaded into nanosponges by freeze-drying method. The particle sizes of plain and quercetin-loaded nanosponges are in between 40 and 100 nm with low polydispersity indices. Zeta potential is sufficiently high to obtain a stable colloidal nanosuspension. Fourier transformed infrared, Raman spectroscopy, differential scanning calorimetry, and X-ray powder diffraction studies confirmed the interaction of quercetin with nanosponges. Particle sizes measured from TEM images were in agreement with DLS results. The dissolution of the quercetin nanosponges was significantly higher compared with the pure drug. The stability of encapsulated quercetin nanosponge was tracked in a simulated intestinal fluid. A marked improvement in the photostability was also observed. In addition, the antioxidant activity of the quercetin nanosponges was more effective than pure quercetin on DPPH scavenging, anti-superoxide formation, and superoxide anion scavenging. These results signify that nanosponge formulations can be used as effective nanocarriers for the delivery of quercetin.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Polysaccharides Composition and Applications · Proteins in Food Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Dias K, Nikolaou S, De Giovani WF (2008) Synthesis and spectral investigation of Al(III) catechin/β-cyclodextrin and Al(III) quercetin/β-cyclodextrin inclusion compounds. Spectrochim Acta A Mol Biomol Spectrosc 70:154–16110.1016/j.saa.2007.07.022 ↗
2. Hollman PC, Katan MB (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 37:937–94210.1016/S0278-6915(99)00079-4 ↗
3. Scambia G, Ranelletti FO, Panici PB et al (1990) Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br J Cancer 62:942–94610.1038/bjc.1990.414 ↗
4. Scambia G, Ranelletti FO, Benedetti Panici P et al (1992) Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II). Gynecol Oncol 45:13–1910.1016/0090-8258(92)90484-Z ↗
5. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–24410.1016/j.jconrel.2008.10.002 ↗
6. Ross JA, Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19–3410.1146/annurev.nutr.22.111401.144957 ↗
7. Gregory S, Kelly ND (2001) Quercetin. Altern Med Rev 16:172–194
8. Chen-yu G, Chun-fen Y, Qi-lu L et al (2012) Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 430:292–29810.1016/j.ijpharm.2012.03.042 ↗
9. Kumari A, Yadav SK, Pakade YB, Singh B, Yadav SC (2010) Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B Biointerfaces 80:184–19210.1016/j.colsurfb.2010.06.002 ↗
10. Wang Q, Bao Y, Ahire J, Chao Y (2013) Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery. Adv Healthc Mater 2:459–46610.1002/adhm.201200178 ↗
11. Ader P, Wessmann A, Wolffram S (2000) Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med 28:1056–106710.1016/S0891-5849(00)00195-7 ↗
12. Mulholland PJ, Ferry DR, Anderson D et al (2001) Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol 12:245–24810.1023/A:1008372017097 ↗
13. Zhang Y, Pan Y, Wang J, Zhang L, Long B, Lıu X (2006) Study on distribution of liposome nanoparticles loaded quercetin in mice. Nanoscience 11:89–94
14. Wang G, Wang JJ, Yang GY et al (2012) Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death. Int J Nanomed 7:271–28010.2147/IJN.S26935 ↗
15. Wu TH, Yen FL, Lin LT, Tsai TR, Lin CC, Cham TM (2008) Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 346:160–16810.1016/j.ijpharm.2007.06.036 ↗
16. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–24410.1016/j.jconrel.2008.10.002 ↗
17. Dhawan S, Kapil R, Singh B (2011) Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 63:342–35110.1111/j.2042-7158.2010.01225.x ↗
18. Sahoo NG, Kakran M, Shaal LA et al (2011) Preparation and characterization of quercetin nanocrystals. J Pharm Sci 100:2379–239010.1002/jps.22446 ↗
19. Fang R, Hao R, Wu X, Li Q, Leng X, Jing H (2011) Bovine serum albumin nanoparticle promotes the stability of quercetin in simulated intestinal fluid. J Agric Food Chem 59:6292–629810.1021/jf200718j ↗
20. Tan Q, Liu W, Guo C, Zhai G (2011) Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 6:1621–163010.2217/nnm.11.142 ↗
21. Wang Q, Bao Y, Ahire J, Chao Y (2013) Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery. Adv Healthc Mater 2:459–46610.1002/adhm.201200178 ↗
22. Manuela C, Giuseppe C, Ortensia IP, Francesca I, Nevio P, Francesco P (2012) Quercetin-imprinted nanospheres as novel drug delivery devices. J Funct Biomater 3:269–28210.3390/jfb3020269 ↗
23. Deepak C, Sanjay KN, Anupama M, Mahesh C, Neeraj K (2012) Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model. Drug Deliv Transl Res 2:112–12310.1007/s13346-012-0063-5 ↗
24. Pool H, Quintanar D, Figueroa JD, Mano CM, Bechara JH, Godínez LA, Mendoza S (2012) Antioxidant effects of quercetin and catechin encapsulated into PLGA nanoparticles. J Nano Mater. doi: 10.1155/2012/145380
25. Bennet D, Marimuthu M, Kim S, An J (2012) Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery. Int J Nanomed 7:3399–3419
26. Smita P, Manjappa AS, Ukawala M, Murthy RSR (2012) PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnol 3:25–3610.1007/s12645-012-0027-y ↗
27. Wang BL, Gao X, Men K et al (2012) Treating acute cystitis with biodegradable micelle-encapsulated quercetin. Int J Nanomed 7:2239–2247
28. Tan BJ, Liu Y, Chang KL, Lim BK, Chiu GN (2012) Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomed 7:651–66110.2217/nnm.11.151 ↗
29. Zheng Y, Haworth IS, Zuo Z, Chow MS, Chow AH (2005) Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes. J Pharm Sci 94:1079–108910.1002/jps.20325 ↗
30. Jullian C, Moyano L, Yañez C, Olea-Azar C (2007) Complexation of quercetin with three kinds of cyclodextrins: an antioxidant study. Spectrochim Acta A Mol Biomol Spectrosc 67:230–23410.1016/j.saa.2006.07.006 ↗
31. Bergonzi MC, Bilia AR, Di Bari L, Mazzi G, Vincieri FF (2007) Studies on the interactions between some flavonols and cyclodextrins. Bioorg Med Chem Lett 17:5744–574810.1016/j.bmcl.2007.08.067 ↗
32. Zheng Y, Chow AH (2009) Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin/quercetin complex. Drug Dev Ind Pharm 35:727–73410.1080/03639040802526805 ↗
33. Carlotti ME, Sapino S, Ugazio E, Caron G (2011) On the complexation of quercetin with methyl-β-cyclodextrin: photostability and antioxidant studies. J Incl Phenom Macrocycl Chem 70:81–9010.1007/s10847-010-9864-7 ↗
34. Challa R, Ahuja A, Ali J, Khar RK (2005) Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6:E329–E35610.1208/pt060243 ↗
35. Szejtli J (1991) Cyclodextrin in drug formulations Part I. Pharm Technol Int 3:15–22
36. Szente L, Szejtli J (1999) Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–2810.1016/S0169-409X(98)00092-1 ↗
37. Lala R, Thorat A, Gargote C (2011) Current trends in β-cyclodextrin based drug delivery systems. Int J Res Ayurveda Pharm 2:1520–1526
38. Ansari KA, Vavia PR, Trotta F, Cavalli R (2011) Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 12:279–28610.1208/s12249-011-9584-3 ↗
39. Swaminathan S, Pastero L, Serpe L et al (2010) Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 74:193–20110.1016/j.ejpb.2009.11.003 ↗
40. Swaminathan S, Vavia PR, Trotta F et al (2013) Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 76:201–21110.1007/s10847-012-0192-y ↗
41. Selvamuthukumar S, Anandam S, Krishnamoorthy K, Rajappan M (2012) Nanosponges: a novel class of drug delivery system—review. J Pharm Pharm Sci 15:103–11110.18433/J3K308 ↗
42. Teslova T, Corredor C, Livingstone R et al (2007) Raman and surface-enhanced Raman spectra of flavone and several hydroxy derivatives. J Raman Spectrosc 38:802–81810.1002/jrs.1695 ↗